{
  "url": "https://struct.news/briefs/anaptysbios-cash-doubled-as-revenue-fell-67-the-financing-footnote-matters",
  "title": "AnaptysBio's cash doubled as revenue fell 67%. The financing footnote matters",
  "summary": "$248.5 million of cash sat on the balance sheet after the three months, but operating cash flow was still negative and revenue had dropped to $25.6 million.",
  "published_at": "2026-09-21T20:27:32.062495+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "AnaptysBio, Inc.",
    "ticker": "ANAB",
    "cik": "1193125",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-05-12",
    "accession": "0001193125-26-219515",
    "url": "https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/anab-20260331.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-11-04",
    "url": "https://www.sec.gov/Archives/edgar/data/1370053/000137005325000089/anab-20250930.htm"
  },
  "reported_figures": [
    {
      "group": "The filing in three numbers",
      "label": "Revenue",
      "value": 234603000,
      "display": "$234.6M",
      "unit": "usd",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "sec_filing",
        "label": "Filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-219515",
        "filing_date": "2026-05-12"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Revenue YoY",
      "value": 157.01468010517092,
      "display": "+157.0%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-219515",
        "filing_date": "2026-05-12"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Operating margin",
      "value": 20.415766209298262,
      "display": "+20.4%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-219515",
        "filing_date": "2026-05-12"
      }
    }
  ],
  "watch_next": [
    {
      "type": "product_pipeline",
      "statement": "R&D spending declined as clinical expenses fell, while salaries and related expenses increased, changing the current pipeline spending mix.",
      "importance": "medium",
      "evidence": "Research and development expenses were $34.0 million during the three months ended March 31, 2026 compared to $41.2 million during the three months ended March 31, 2025, for a decrease of $7.2 million, primarily due to a $7.8 million decrease in clinical expenses",
      "source_date": "2026-05-12"
    },
    {
      "type": "litigation",
      "statement": "Legal expense increased because of the GSK lawsuit and business separation activity, weighing on general and administrative costs.",
      "importance": "medium",
      "evidence": "The increase is primarily due to an $8.3 million increase in legal expenses due to the GSK lawsuit and activity related to the separation of the business",
      "source_date": "2026-05-12"
    }
  ],
  "related_tickers": [
    "ANAB"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}